

Mario 1 – Study IPI-549-01 Manuscript
Supplementary Data and Methods

Table S3. Summary of anti-tumor activity endpoints in patients treated with eganelisib combination therapy by tumor type (n=180)

	Part C (eganelisib dose escalation + nivolumab)				Part E				Part F	Part G			Part H
	Eganelisib dose				NSCLC	Melanoma	SCCHN	Total	TNBC	ACC	Mesothelioma	Total	High-circulating MDSCs
	20 mg (n=7)	30 mg (n=12)	40 mg (n=12)	Total (n=31)	(n=20)	(n=40)	(n=21)	(n=81)	(n=29)	(n=5)	(n=11)	(n=16)	(n=23)
ORR (CR+PR) ^{a,b}													
n	6	11	11	28	20	39	21	80	27	5	11	16	18
ORR	0	1 (9.1)	1 (9.1)	2 (7.1)	1 (5.0)	4 (10.3)	2 (9.5)	7 (8.8)	2 (7.4)	0	1 (9.1)	1 (6.3)	0
95% exact binomial CI	[0.0, 45.9]	[0.2, 41.3]	[0.2, 41.3]	[0.9, 23.5]	[0.1, 24.9]	[2.9, 24.2]	[1.2, 30.4]	[3.6, 17.2]	[0.9, 24.3]	[0.0, 52.2]	[0.2, 41.3]	[0.2, 30.2]	[0.0, 18.5]
DCR (CR+PR+SD) ^a													
n	6	11	11	28	20	39	21	80	27	5	11	16	18
DCR	1 (16.7)	6 (54.5)	4 (36.4)	11 (39.3)	8 (40.0)	14 (35.9)	9 (42.9)	31 (38.8)	8 (29.6)	1 (20.0)	6 (54.5)	7 (43.8)	4 (22.2)
95% exact binomial CI	[0.4, 64.1]	[23.4, 83.3]	[10.9, 69.2]	[21.5, 59.4]	[19.1, 63.9]	[21.2, 52.8]	[21.8, 66.0]	[28.1, 50.3]	[13.8, 50.2]	[0.5, 71.6]	[23.4, 83.3]	[19.8, 70.1]	[6.4, 47.6]
Best overall response ^a													
n	7	12	12	31	20	40	21	81	29	5	11	16	23
CR	0	0	0	0	0	0	0	0	1 (3.4)	0	0	0	0
PR	0	1 (8.3)	1 (8.3)	2 (6.5)	1 (5.0)	4 (10.0)	2 (9.5)	7 (8.6)	1 (3.4)	0	1 (9.1)	1 (6.3)	0
SD	1 (14.3)	5 (41.7)	3 (25.0)	9 (29.0)	7 (35.0)	10 (25.0)	7 (33.3)	24 (29.6)	6 (20.7)	1 (20.0)	5 (45.5)	6 (37.5)	4 (17.4)
PD	3 (42.9)	4 (33.3)	4 (33.3)	11 (35.5)	10 (50.0)	21 (52.5)	10 (47.6)	41 (50.6)	13 (44.8)	1 (20.0)	3 (27.3)	4 (25.0)	10 (43.5)
NE	2 (28.6)	1 (8.3)	3 (25.0)	6 (19.4)	2 (10.0)	4 (10.0)	2 (9.5)	8 (9.9)	6 (20.7)	3 (60.0)	2 (18.2)	5 (31.3)	4 (17.4)
CBR-24 ^{b,c}													
n	6	11	11	28	20	39	21	80	27	5	11	16	18
CB	1 (16.7)	2 (18.2)	1 (9.1)	4 (14.3)	3 (15.0)	7 (17.9)	5 (23.8)	15 (18.8)	2 (7.4)	1 (20.0)	2 (18.2)	3 (18.8)	1 (5.6)
95% exact binomial CI	[0.4, 64.1]	[2.3, 51.8]	[0.2, 41.3]	[4.0, 32.7]	[3.2, 37.9]	[7.5, 33.5]	[8.2, 47.2]	[10.9, 29.0]	[0.9, 24.3]	[0.5, 71.6]	[2.3, 51.8]	[4.0, 45.6]	[0.1, 27.3]
CBR-16 ^{b,c}													
n	6	11	11	28	20	39	21	80	27	5	11	16	18
CB	1 (16.7)	4 (36.4)	2 (18.2)	7 (25.0)	3 (15.0)	7 (17.9)	5 (23.8)	15 (18.8)	4 (14.8)	1 (20.0)	3 (27.3)	4 (25.0)	1 (5.6)
95% exact binomial CI	[0.4, 64.1]	[10.9, 69.2]	[2.3, 51.8]	[10.7, 44.9]	[3.2, 37.9]	[7.5, 33.5]	[8.2, 47.2]	[10.9, 29.0]	[4.2, 33.7]	[0.5, 71.6]	[6.0, 61.0]	[7.3, 52.4]	[0.1, 27.3]
TTR, months ^d													
Median [95% CI]	-	1.7 [NA, NA]	1.9 [NA, NA]	1.8 [1.7, NA]	1.8 [NA, NA]	5.6 [1.8, NA]	1.9 [1.8, NA]	2.1 [1.8, 9.7]	1.8 [1.8, NA]	-	2.0 [NA, NA]	2.0 [NA, NA]	-
DOR, months ^d													
PD or died, n	-	1	1	2	0	3	2	5	2	-	1	1	-
Censored, n	-	0	0	0	1	2	0	3	1	-	0	0	-
Median [95% CI]	-	11.4 [NA, NA]	9.3 [NA, NA]	10.3 [9.3, NA]	NA [NA, NA]	8.9 [3.8, NA]	6.5 [3.8, NA]	8.9 [3.8, NA]	7.5 [1.9, NA]	-	10.9 [NA, NA]	10.9 [NA, NA]	-
DOT, months													
TF ^e , n	6	12	11	29	17	33	20	70	27	4	9	13	18
Censored, n	1	0	1	2	3	7	1	11	2	1	2	3	5
Median [95% CI]	1.6 [0.0, 3.3]	2.6 [1.1, 11.3]	2.0 [0.5, 4.0]	1.9 [1.4, 3.5]	2.8 [1.9, 3.5]	2.3 [1.9, 4.0]	3.5 [1.9, 5.9]	2.7 [1.9, 3.5]	1.9 [1.7, 2.5]	3.3 [0.5, NA]	4.7 [1.4, NA]	3.3 [1.4, 12.0]	1.9 [1.0, 3.3]
PFS, months													
Death or PD, n	6	11	9	26	16	33	20	69	25	2	8	10	18
Censored, n	1	1	3	5	4	7	1	12	4	3	3	6	5
Median [95% CI]	1.6 [0.0, 1.9]	3.5 [1.8, 7.4]	1.9 [0.9, NA]	1.9 [1.6, 4.0]	2.1 [1.8, 3.9]	1.9 [1.8, 3.7]	3.7 [1.9, 5.5]	2.0 [1.9, 3.7]	1.9 [1.8, 2.3]	NA [0.5, NA]	5.8 [1.3, NA]	5.8 [1.5, 12.8]	1.8 [1.1, 3.7]
OS, months													
Deaths, n	3	4	2	9	8	15	15	38	11	1	6	7	10
Censored, n	4	8	10	22	12	25	6	43	18	4	5	9	13
Median [95% CI]	NA [0.6, NA]	18.0 [3.7, NA]	NA [3.2, NA]	18.0 [3.7, NA]	9.2 [3.9, NA]	18.1 [9.9, 32.8]	9.4 [5.7, 13.8]	10.2 [9.2, 14.1]	14.3 [2.6, NA]	NA [1.4, NA]	11.7 [1.5, NA]	12.0 [5.3, NA]	6.5 [2.6, 8.4]

Abbreviations: AE, adverse event; CB, clinical benefit; CBR, clinical benefit rate; CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; DOT, duration of treatment; NA, not applicable; NE, not evaluable; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PD, progressive disease; PR, partial response; SD, stable disease; TF, treatment failure; TTR, time to response.

Time to event parameters were estimated using Kaplan-Meier method.

^aBased on investigator assessment.

^bCalculated based on response evaluable set within the monotherapy or combination therapy cohort.

^cCBR is defined as achieving confirmed CR, PR or SD of at least 24 weeks (CBR-24) or 16 weeks (CBR-16) from cycle 1 day 1.

^dAnalyzed for responders only.

^eDefined as discontinuation due to AEs, progressive disease, and death.